Picture of Benchmark Holdings logo

BMK — Benchmark Holdings News Story

0.000.00%
gb flag iconLast trade - 00:00
Consumer DefensivesAdventurousSmall CapNeutral

Q1 Results

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230228:nRSb2203Ra&default-theme=true

RNS Number : 2203R  Benchmark Holdings PLC  28 February 2023

28 February 2023

 

Information within this announcement is deemed by the Company to constitute
inside information under the Market Abuse Regulations (EU) No. 596/2014

 

Benchmark Holdings plc

("Benchmark", the "Company" or the "Group")

 

Q1 Results

(Three months ended 31 December 2022)

 

 Excellent start to the year with growth in all business areas and
significant uplift in Health

 

In compliance with the terms of the Company's unsecured Green bond, which
requires it to publish quarterly financial information, Benchmark, the
aquaculture biotechnology business, announces its unaudited results for the
three months ended 31 December 2022 (the "Period"), which constitute the first
quarter for the fiscal year ("FY") 2023. All Q1 FY22 and Q1 FY23 figures
quoted in this announcement are based on unaudited accounts.

Financial highlights

Continuation of consistent year-on-year growth in Revenue and Adjusted EBITDA
on a rolling twelve month basis

·    Q1 FY23 revenues were £54.5m, 36% ahead of the prior year (+29% CER)

o  Genetics delivered strong revenue growth 41% above Q1 FY22, driven
primarily by higher sales of salmon eggs and harvest revenues

o  Advanced Nutrition also reported strong growth with revenues 19% above Q1
FY22, benefitting from continued positive trading and forex movements

o  Health reported excellent growth with revenues 80% above Q1 FY22, driven
by increased adoption of Ectosan® Vet and CleanTreat® and significantly
higher sales of Salmosan® Vet

·    Q1 FY23 Adjusted EBITDA excluding fair value movements from
biological assets increased 61% (+56% CER) to £12.1m as a result of higher
revenues, higher asset utilisation and continued cost discipline

o  Notably, Adjusted EBITDA in Health increased substantially to £4.1m in
the quarter (Q1 FY22: £0.5m) demonstrating the potential of this business
area to deliver good profitability

o  Group Adjusted EBITDA margin of 22% excluding fair value movements from
biological assets (Q1 FY22:19%)

·    Net operating loss of £0.1m (Q1 FY22: £1.5m loss)

·    Net loss of -£0.7m significantly reduced from prior year (Q1 FY22:
-£5.1m)

·    Cash inflow from operating activities of £8.1m (Q1 FY22: inflow
£1.1m)

·    Cash, liquidity and net debt all improved compared to the year end
position:

o  Cash of £42.8m and liquidity of £62.8m (cash and available facility)

o  Reduced net debt excluding lease liabilities of £37.9m (30 September
2022: £47.5m)

o  Includes benefit of net proceeds from the fundraise in December 2022 of
£11.6m

Operational highlights

·    Advanced Nutrition - continued good performance despite relative
softness in the shrimp market

o  Growth in all product areas

o  Adjusted EBITDA margin in line with prior year at 23% (Q1 FY22: 23%)
benefitting from success of new commercial focus, cost discipline and ongoing
actions to improve efficiency and asset utilisation offsetting cost inflation

o  Continued innovation with pre-launch of new artemia tool which counts
hatched Artemia

·    Genetics - Continued growth in salmon egg sales with record number of
eggs sold

o  118m eggs sold in Q1 FY23 (Q1 FY22: 76m eggs) demonstrating continued
success in meeting increased customer demand supported by recent investment in
incubation unit in Iceland

o  Temporary slowdown in commercialisation of shrimp genetics (SPR shrimp) in
order to refine product offering based on customer feedback from first
commercial cycle. Expect to relaunch commercial effort in H2

o  Post period end, acquisition of remaining 10.52% minority interest in its
subsidiary Benchmark Genetics Iceland, ensuring Benchmark receives the full
benefit from its successful salmon genetics business in Iceland which
represents 50% of the Group's salmon egg capacity

o  Exploring strategic alternatives for tilapia breeding activities

·    Health - Significant increase in customer adoption of  Ectosan® Vet
and CleanTreat®

o  Significant growth in customer adoption of Ectosan® Vet and CleanTreat®
with repeat orders and new client wins which resulted in improved capacity
utilisation and strong profitability

o  Progress made towards development of new business model for Ectosan® Vet
and CleanTreat® aimed at reducing infrastructure costs and capex

§ Timing of commercial launch of integrated wellboat projects subject to
availability and adoption of new large wellboats by customers

§ Progress being made around Customer owned PSV's which represent a viable
alternative in the medium to long term

Oslo Børs listing

§ Progress towards listing on the Oslo Børs, the leading seafood and
aquaculture listing venue globally; ongoing shareholder consultation on
whether to maintain an AIM listing

 

Current trading and outlook

·    Strong Q1 FY23 performance and continued positive trading post period
end. Encouraging outlook for the full year

o  Genetics - good visibility of revenues

o  Advanced Nutrition - continuing positive performance despite some softness
in the shrimp market

o  Health - increasing evidence of customer growing adoption of Ectosan® Vet
and CleanTreat®

Financial Summary

 £m                                                             Q1 FY23   Q1 FY22   % AER  % CER(**)  FY22

                                                                                                      (full year)
 Revenue                                                        54.5     40.0       +36%   +29%       158.3
 Adjusted
 Adjusted EBITDA(1)                                             11.0     7.4        +48%   +44%       31.2
 Adj. EBITDA excluding fair value movement in biological asset  12.1     7.5        +61%   +56%       29.6
 Adjusted Operating Profit(2)                                   5.7      2.5        +131%  +127%      9.1
 Statutory
 Operating loss                                                 (0.1)    (1.5)      +92%   +86%       (7.9)
 Profit/(loss) before tax                                       0.1      (3.7)      +103%  +114%      (23.2)
 Loss for the period                                            (0.7)    (5.1)      +87%   +96%       (30.5)
 Basic loss per share (p)                                       (0.18)   (0.79)                       (4.60)
 Net debt(3)                                                    (61.4)   (64.3)                       (73.7)
 Net debt excluding lease liabilities                           (37.9)   (43.1)                       (47.5)

Business Area summary

 £m                                                                       Q1 FY23  Q1 FY22  % AER  % CER(**)  FY22

                                                                                                              (full year)
 Revenue
 Advanced Nutrition                                                       22.7     19.1     +19%   +4%        80.3
 Genetics                                                                 21.4     15.2     +41%   +42%       58.0
 Health                                                                   10.4     5.8      +80%   +80%       20.1
 Adjusted EBITDA(1)
 Advanced Nutrition                                                       5.3      4.3      +23%   +9%        19.0
 Genetics                                                                 2.6      3.3      -21%   -10%       16.0
 -       Genetics net of fair value movements in biological assets        3.7      3.4      +11%   +19%       14.4
 Health                                                                   4.1      0.5      +643%  +635%      0.1

 

*Constant exchange rate (CER) figures derived by retranslating current year
figures using previous year's foreign exchange rates

(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items

(2) Adjusted Operating Profit is operating gain or loss before exceptional
items and amortisation of intangible assets excluding development costs

(3) Net debt is cash and cash equivalents less loans and borrowings

 

Trond Williksen, CEO, commented:

 

"Benchmark has had an excellent start to the year, again showing a
continuation of the consistent growth we have seen in revenues and net
operating profit on a twelve month rolling basis. This is the result of a good
performance in all our business areas. In particular, it is pleasing to see
traction in our Health business driven by significantly higher adoption of our
sea lice solutions, contributing to a positive financial performance for the
quarter."

 

"We are making progress towards our goal of up-listing to the Oslo Børs, the
preeminent listing venue for aquaculture and seafood companies globally. This
will enable us to increase our visibility with a dedicated group of analysts
and investors."

 

"We are grateful to our existing shareholders for their support through the
years and we are committed to continuing to deliver improved financial
performance and strategic progress for the benefit of all our stakeholders."

 

Analyst / investor presentation and webcast being held today

 

Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial
Officer will host an in-person presentation for analysts and institutional
investors today at 9.00 am CET/8.00 am UK time. The presentation will take
place at Hotel Continental, Stortingsgata 24/26, 0117 Oslo.

 

A live webcast of the presentation is available for analysts and investors to
join remotely at the following link:
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20230228_7
(https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20230228_7)
 

 

Enquiries

 

 For further information, please contact:
 Benchmark Holdings plc                           benchmark@mhpgroup.com
 Trond Williksen, CEO
 Septima Maguire, CFO
 Ivonne Cantu, Investor Relations

 Numis (Broker and NOMAD)                         Tel:  +44(0) 20 7260 1000
 James Black, Freddie Barnfield, Duncan Monteith

 MHP                                              Tel:  +44(0) 20 3128 8004
 Katie Hunt, Reg Hoare, Veronica Farah            benchmark@mhpgroup.com (mailto:benchmark@mhpgroup.com)

 

 

About Benchmark

Benchmark is a market leading aquaculture biotechnology company. Benchmark's
mission is to drive sustainability in aquaculture by delivering products and
solutions in genetics, advanced nutrition and health which improve yield,
growth and animal health and welfare.

Through a global footprint in 26 countries and a broad portfolio of products
and solutions, Benchmark addresses many of the major aquaculture species -
salmon, shrimp, sea bass and sea bream, and tilapia -   in all the major
aquaculture regions around the world. Find out more at www.benchmarkplc.com

Management Report

 

The Group delivered excellent performance in the first three months of the
year translating into a 36% growth in revenue and 61% growth in Adjusted
EBITDA excluding fair value movements from biological assets. Performance was
good across all business areas, with each business area reporting improved
revenues and Adjusted EBITDA excluding fair value movements from biological
assets when compared to the same period last year. On a constant exchange rate
basis, Group revenue and Adjusted EBITDA excluding fair value movements were
up 29% and 56% respectively.

 

Other operating costs were £11.8m, a 18% increase from the prior year (Q1
FY22: £9.9m) due to cost inflation and the impact of forex movements. By
business area, operating costs increased more significantly in Genetics
reflecting the investment in growth vectors including SPR shrimp, tilapia and
salmon in Chile.  R&D expenses for the Group of £1.6m were in line with
the prior year. Total R&D investment including capitalised development
costs was £1.6m (Q1 FY22: £2.3m), reflecting commercialisation of SPR shrimp
during the previous year for which costs are no longer capitalised.

 

Adjusted EBITDA (excluding fair value movement from biological assets) was
£12.1m (Q1 FY22: £7.5m) driven by higher revenues, increased asset
utilisation and ongoing cost control. As a result, the Group achieved an
Adjusted EBITDA margin (excluding fair value movement from biological assets)
of 22% (Q1 FY22: 19%).  Depreciation and amortisation increased 13% from the
comparative period last year to £10.1m (Q1 FY22: £8.9m) as a result of
investment in the businesses and £0.5m impairment of intangible assets in the
Health business area which are no longer being utilised.  Exceptional costs
incurred in the period of £1.0m (Q1 FY22: £nil) related to costs associated
with the listing on Euronext Growth Oslo and preparation for up-listing on the
Oslo stock exchange. However, despite these increased costs, the Group
reported only a small operating loss of £0.1m, a significant improvement from
the £1.5m loss in Q1 FY22.

 

Net finance income in the period was £0.2m (Q1 FY22: £2.2m expense), with a
£2.5m credit relating to the ineffectively hedged portion of the movement in
the fair value of derivate instruments and a lower amortisation charge on
capitalised borrowing fees of £0.1m (Q1 FY22: £0.3m charge) offsetting the
increased interest charges (-£0.3m) following the refinancing exercise.

 

The Group reported a small profit before tax of £0.1m (Q1 FY22: loss before
tax £3.7m); the loss after tax for the period was £0.7m (Q1 FY22: loss after
tax £5.1m).

 

The Group's improved result translated in a significantly higher net operating
cash inflow from operating activities for the period at £8.1m (Q1 FY22:
inflow £1.1m).  This was after an increase in working capital of £0.8m and
tax payments of £1.5m in the period. Net cash used in investing activities
was £2.2m (Q1 FY22: £2.6m) of which capex was £1.9m (Q1 FY22: £2.5m).
Capex in the period related to investment in Genetics (£1.3m), Nutrition
(£0.4m) and in Health (£0.2m).  Net cash inflow from financing activities
was £2.2m, with net proceeds from the fundraise in December 2022 of £11.6m
being offset by £4.4m repayment of debt, £0.6m of capitalised borrowing
fees, £2.2m of interest paid and £2.2m of lease payments.  Net increase in
cash in the quarter was £8.1m to leave the period end cash position at
£42.8m and liquidity of £62.8m.

 

Advanced Nutrition

 

Advanced Nutrition revenues were £22.7m, up 19% with sales higher in all
product areas, also aided by favourable forex rates in the period (revenues
increased at CER by 4%). By product area, sales of Artemia were +23%, Diets
+10% and Health +27% higher than Q1 FY22.  Q1 FY23 Adjusted EBITDA was
£5.3m, up by 23% reflecting improved asset utilisation and ongoing cost
discipline. Adjusted EBITDA margin was consistent at 23% (Q1 FY22: 23%).
Notably, the Company's good performance in Advanced Nutrition was delivered
against a backdrop of soft market conditions entering into FY23 affected by
weather conditions in Thailand, the presence of SHIV virus in Indonesia and in
Latin America by high fuel costs combined with low farm gate prices.

 

Our continued growth in Advanced Nutrition revenues is a reflection of our
focused commercial effort which brings together our market leading, high
performing product portfolio, experienced technical support and a quality
oriented, reliable supply chain. We continue to innovate both in our existing
range and development of new products and during the period we carried out a
pre-launch of our Artemia counter, adding to our suite of Artemia technologies
to improve customer experience. Examples of our customer-centric commercial
effort in the period include trials of our specialist diets conducted by our
global and regional technical experts working together to optimise customer
performance in Indonesia, and artemia workshops conducted by our regional
technical support and local sales teams aimed at tailoring the use of artemia
tools and hatching protocols to individual customer needs.

 

Genetics

Genetics delivered revenues of £21.4m in Q1 FY23 (Q1 FY22: £15.2m),
reflecting a strong growth of 41% (+42% CER). This was driven primarily by
sales of salmon eggs and harvest income which increased by 57% and 31%,
respectively. Revenues from genetic services, our consulting business were 14%
ahead of Q1 FY22. There was a slowdown in the commercial roll-out of the SPR
shrimp as we refine our product offering based on customer feedback in our
first year of trading. As a result, sales from SPR shrimp were 20% below the
prior year.

Adjusted EBITDA for Q1 FY23 (excluding fair value movements of biological
assets) was £3.7m, 11% ahead of the prior year (Q1 FY22: £3.4m), and at
constant exchange rates, was 19% higher than the prior year.  The fair value
movements on biological assets in the quarter was a £1.1m reduction in value
(Q1 FY22: £0.1m reduction), so Adjusted EBITDA including fair value movements
for Q1 FY23 was £2.6m (Q1 FY22: £3.3m).

Post period end the Company announced the retirement of Jan-Emil Johannessen,
Head of Benchmark Genetics who will be succeeded by Geir Olav Melingen,
currently Commercial Director Salmon at Benchmark, with effect from 1 June
2023. During his tenure Jan-Emil has built a talented and experienced team
capable of taking Benchmark Genetics through the next phase of growth.  Geir
Olav Melingen has extensive experience from leading roles in the aquaculture
industry including at MSD, as CEO of Fishguard and CEO of the Bergen Aquarium.
He has deep experience in fish health and the salmon industry with a PhD in
fish health from the University of Bergen.

 

Health

Revenues in Q1 FY23 were £10.4m (Q1 FY22: £5.8m) as a result of
significantly increased customer uptake and sales of Ectosan® Vet and
CleanTreat® and significant growth in Salmosan Vet - our well established sea
lice treatment.  Revenues from Ectosan® Vet and CleanTreat® were £7.5m of
which £1.7m was derived from recharging vessel and fuel costs associated with
the Ectosan® Vet and CleanTreat® operations.

Revenues from Salmosan® Vet, our long-established sea lice treatment were
£2.9m (Q1 FY22: £1.3m) with significant growth achieved in Canada, Norway
and the Faroe Islands. Growth was driven by a variation to the marketing label
which supports a longer product exposure, as well as enhanced engagement with
customers through our portfolio of sea lice solutions which can be used in
combination to address our customers' sea lice challenge.

The significant increase in revenues resulted in Adjusted EBITDA of £4.1m in
the quarter (Q1 FY22: £0.5m) demonstrating the potential of this business
area to deliver good profitability.

Operationally we continue to make improvements in the efficiency of the
delivery of our Ectosan® Vet and CleanTreat® solution achieving a new record
in the speed of water transfer between the treatment wellboat and the
CleanTreat® units, a key parameter for our customers. Speed of water transfer
is now approximately double what it was at launch.

 

In the period we made progress towards a new business model for Ectosan® Vet
and CleanTreat® aimed at lowering the Company's exposure to infrastructure
costs by lowering capital intensity and capital investment. The Company has
established a partnership with leading specialist wellboat equipment provider
MMC and ship designer SALT to capture opportunities to integrate its
CleanTreat® systems into new wellboats coming to the market. The speed of
adoption of a fully integrated solution on wellboats is reliant on the
availability and customer adoption of new large wellboats.  Customer owned
PSV's/platforms are a viable alternative to large wellboats in the medium to
long term.

 

Oslo Børs uplisting and delisting from AIM

As previously announced at the end of FY22, the Company intends to up-list
from Euronext Growth Oslo to the Oslo Børs and we are making progress towards
this goal.  Oslo is the leading listing venue for aquaculture and seafood
companies. There are 27 listed companies in the seafood sector in Oslo while
Benchmark is the only pure play aquaculture company listed on the London Stock
Exchange.  A listing on the Oslo Børs provides natural access to an
important pool of specialist investors best equipped to recognise the
Company's added value and growth potential. The Company is conducting a
consultation with shareholders on whether to maintain a listing on AIM.  The
potential up-listing to the Oslo Børs and delisting from AIM are subject to
shareholder approval and market conditions.

 

Current Trading and Outlook

 

Post period end the Company continues to perform well across all business
areas and the outlook for the full year is encouraging. This reflects good
visibility of revenues in Genetics, a positive performance in Advanced
Nutrition despite soft shrimp markets, and increasing evidence of customer
adoption for Ectosan® Vet and CleanTreat® in Health.

 

 

Benchmark Holdings plc

Consolidated Income Statement for the period ended 31 December 2022

 

 

 All figures in £000's                                             Notes  Q1 2023       Q1 2022       FY 2022

(unaudited)
(unaudited)
(audited)
 Revenue                                                           4      54,495        40,014        158,277
 Cost of sales                                                            (30,268)      (20,515)      (75,149)
 Gross profit                                                             24,227        19,499        83,128
 Research and development costs                                           (1,563)       (1,647)       (6,691)
 Other operating costs                                                    (11,753)      (9,923)       (44,661)
 Share of profit/(loss) of equity-accounted investees, net of tax         56            (504)         (595)
 Adjusted EBITDA²                                                         10,967        7,425         31,181
 Exceptional items                                                 5      (972)         -             16
 EBITDA¹                                                                  9,995         7,425         31,197
 Depreciation and impairment                                              (4,615)       (4,495)       (19,897)
 Amortisation and impairment                                              (5,502)       (4,388)       (19,161)
 Operating loss                                                           (122)         (1,458)       (7,861)
 Finance cost                                                             (7,286)       (2,343)       (20,057)
 Finance income                                                           7,508         119           4,741
 Profit/(loss) before taxation                                            100           (3,682)       (23,177)
 Tax on loss                                                       6      (779)         (1,427)       (7,274)
 Loss for the period                                                      (679)         (5,109)       (30,451)
 Loss for the period attributable to:
 - Owners of the parent                                                   (1,283)       (5,357)       (32,087)
 - Non-controlling interest                                               604           248           1,636
                                                                          (679)         (5,109)       (30,451)

 Earnings per share
 Basic loss per share (pence)                                      7      (0.18)        (0.79)        (4.60)
 Diluted loss per share (pence)                                    7      (0.18)        (0.79)        (4.60)

 

1 EBITDA - Earnings before interest, tax, depreciation, amortisation, and
impairment

2 Adjusted EBITDA - EBITDA before exceptional items

 

 

 

Benchmark Holdings plc

Consolidated Statement of Comprehensive Income for the period ended 31
December 2022

 

 

 All figures in £000's                                                     Q1 2023       Q1 2022       FY 2022

(unaudited)
(unaudited)
(audited)

 Loss for the period                                                       (679)         (5,109)       (30,451)
 Other comprehensive income
 Items that are or may be reclassified subsequently to profit or loss
 Foreign exchange translation differences                                  (18,040)      (2,611)       47,606
 Cash flow hedges - changes in fair value                                  (516)         (134)         2,627
 Cash flow hedges - reclassified to profit or loss                         (113)         115           2,546
 Total comprehensive income for the period                                 (19,348)      (7,739)       22,328

 Total comprehensive income for the period attributable to:
 - Owners of the parent                                                    (19,751)      (7,948)       20,326
 - Non-controlling interest                                                403           209           2,002
                                                                           (19,348)      (7,739)       22,328

 

The accompanying notes are an integral part of this consolidated financial
information.

Benchmark Holdings plc

Consolidated Balance Sheet as at 31 December 2022

 

 

                                                                          31 December 2022  31 December 2021  30 September 2022
 All figures in £000's                                             Notes  (unaudited)       (unaudited)       (audited)
 Assets
 Property, plant and equipment                                            80,505            78,082            81,900
 Right-of-use assets                                                      23,883            23,062            27,034
 Intangible assets                                                        224,606           224,192           245,264
 Equity-accounted investees                                               3,041             2,815             3,113
 Other investments                                                        15                15                15
 Biological and agricultural assets                                       24,930            21,206            20,878
 Trade and other receivables                                              422               -                 -
 Non-current assets                                                       357,402           349,372           378,204
 Inventories                                                              28,222            21,343            29,813
 Biological and agricultural assets                                       17,154            17,137            25,780
 Trade and other receivables                                              51,159            43,267            56,377
 Cash and cash equivalents                                                42,782            52,705            36,399
 Current assets                                                           139,317           134,452           148,369
 Total assets                                                             496,719           483,824           526,573
 Liabilities
 Trade and other payables                                                 (35,254)          (39,001)          (44,324)
 Loans and borrowings                                              8      (16,227)          (6,872)           (17,091)
 Corporation tax liability                                                (10,349)          (6,936)           (10,211)
 Provisions                                                               (1,587)           (557)             (1,631)
 Current liabilities                                                      (63,417)          (53,366)          (73,257)
 Loans and borrowings                                              8      (87,958)          (110,119)         (93,045)
 Other payables                                                           (4,369)           (895)             (8,996)
 Deferred tax                                                             (25,105)          (27,159)          (27,990)
 Non-current liabilities                                                  (117,432)         (138,173)         (130,031)
 Total liabilities                                                        (180,849)         (191,539)         (203,288)
 Net assets                                                               315,870           292,285           323,285
 Issued capital and reserves attributable to owners of the parent
 Share capital                                                     9      739               704               704
 Additional paid-in share capital                                  9      432,423           420,754           420,824
 Capital redemption reserve                                               5                 5                 5
 Retained earnings                                                        (186,120)         (159,269)         (185,136)
 Hedging reserve                                                          (1,332)           (5,895)           (703)
 Foreign exchange reserve                                                 59,866            27,893            77,705
 Equity attributable to owners of the parent                              305,581           284,192           313,399
 Non-controlling interest                                                 10,289            8,093             9,886
 Total equity and reserves                                                315,870           292,285           323,285

 

The accompanying notes are an integral part of this consolidated financial
information.

Benchmark Holdings plc

Consolidated Statement of Changes in Equity for the period ended 31 December
2022

 

 

                                                      Share     Additional paid-in share capital*      Other      Hedging      Retained     Total attributable       Non-          Total

capital
reserves
reserve
 earnings
 to equity holders of
controlling
equity

parent
interest
                                                      £000      £000                                   £000       £000         £000         £000                     £000          £000

 As at 1 October 2022 (audited)                      704       420,824                                77,710     (703)        (185,136)    313,399                  9,886         323,285
 Comprehensive income for the period
 (Loss)/profit for the period                        -         -                                      -          -            (1,283)      (1,283)                  604           (679)
 Other comprehensive income                          -         -                                      (17,839)   (629)        -            (18,468)                 (201)         (18,669)
 Total comprehensive income for the period           -         -                                      (17,839)   (629)        (1,283)      (19,751)                 403           (19,348)
 Contributions by and distributions to owners
 Share issue                                         35        12,985                                 -          -            -            13,020                   -             13,020
 Share issue costs recognised through equity         -         (1,386)                                -          -            -            (1,386)                  -             (1,386)
 Share-based payment                                 -         -                                      -          -            299          299                      -             299
 Total contributions by and distributions to owners  35        11,599                                 -          -            299          11,933                   -             11,933
 Total transactions with owners of the Company       35        11,599                                 -          -            299          11,933                   -             11,933
 As at 31 December 2022 (unaudited)                  739       432,423                                59,871     (1,332)      (186,120)    305,581                  10,289        315,870

 As at 1 October 2021 (audited)                      670       400,682                                30,470     (5,876)      (154,231)    271,715                  7,884         279,599
 Comprehensive income for the period
 (Loss)/profit for the period                        -         -                                      -          -            (5,357)      (5,357)                  248           (5,109)
 Other comprehensive income                          -         -                                      (2,572)    (19)         -            (2,591)                  (39)          (2,630)
 Total comprehensive income for the period           -         -                                      (2,572)    (19)         (5,357)      (7,948)                  209           (7,739)
 Contributions by and distributions to owners
 Share issue                                         34        20,634                                 -          -            -            20,668                   -             20,668
 Share issue costs recognised through equity         -         (562)                                  -          -            -            (562)                    -             (562)
 Share-based payment                                 -         -                                      -          -            319          319                      -             319
 Total contributions by and distributions to owners  34        20,072                                 -          -            319          20,425                   -             20,425
 Total transactions with owners of the Company       34        20,072                                 -          -            319          20,425                   -             20,425
 As at 31 December 2021 (unaudited)                  704       420,754                                27,898     (5,895)      (159,269)    284,192                  8,093         292,285

 As at 1 October 2021 (audited)                      670       400,682                                30,470     (5,876)      (154,231)    271,715                  7,884         279,599
 Comprehensive income for the period
 (Loss)/profit for the period                        -         -                                      -          -            (32,087)     (32,087)                 1,636         (30,451)
 Other comprehensive income                          -         -                                      47,240     5,173        -            52,413                   366           52,779
 Total comprehensive income for the period           -         -                                      47,240     5,173        (32,087)     20,326                   2,002         22,328
 Contributions by and distributions to owners
 Share issue                                         34        20,704                                 -          -            -            20,738                   -             20,738
 Share issue costs recognised through equity         -         (562)                                  -          -            -            (562)                    -             (562)
 Share-based payment                                 -         -                                      -          -            1,182        1,182                    -             1,182
 Total contributions by and distributions to owners  34        20,142                                 -          -            1,182        21,358                   -             21,358
 Total transactions with owners of the Company       34        20,142                                 -          -            1,182        21,358                   -             21,358
 As at 30 September 2022 (audited)                   704       420,824                                77,710     (703)        (185,136)    313,399                  9,886         323,285

 

*Other reserves in this statement is an aggregation of capital redemption
reserve and foreign exchange reserve.

 

The accompanying notes are an integral part of this consolidated financial
information.

Benchmark Holdings plc

Consolidated Statement of Cash Flows for the period ended 31 December 2022

 

 

                                                                   Q1 2023 (unaudited)  Q1 2022 (unaudited)  FY 2022 (audited)
                                                                   £000                 £000                 £000
 Cash flows from operating activities
 Loss for the period                                               (679)                (5,109)              (30,451)
 Adjustments for:
 Depreciation and impairment of property, plant and equipment      2,033                2,022                8,602
 Depreciation and impairment of right-of-use assets                2,582                2,473                11,295
 Amortisation and impairment of intangible fixed assets            5,502                4,388                19,161
 Loss on sale of property, plant and equipment                     (37)                 -                    (43)
 Finance income                                                    (7,508)              (119)                (319)
 Finance costs                                                     7,010                2,247                18,437
 Increase in fair value of contingent consideration receivable     -                    -                    (1,203)
 Share of (profit)/loss of equity-accounted investees, net of tax  (56)                 504                  595
 Foreign exchange losses/(gains)                                   418                  (9)                  (3,985)
 Share-based payment expense                                       299                  319                  1,182
 Other adjustments for non-cash items                              -                    -                    (276)
 Tax charge                                                        779                  1,427                7,274
 Decrease/(increase) in trade and other receivables                4,011                2,683                (8,511)
 Decrease/(increase) in inventories                                1,571                (880)                (5,406)
 Decrease/(increase) in biological and agricultural assets         3,294                (138)                (6,099)
 (Decrease)/increase in trade and other payables                   (9,633)              (7,687)              6,946
 (Decrease)/increase in provisions                                 (9)                  (6)                  1,058
                                                                   9,577                2,115                18,257
 Income taxes paid                                                 (1,509)              (981)                (7,447)
 Net cash flows generated from operating activities                8,068                1,134                10,810
 Investing activities
 Purchase of investments                                           (63)                 -                    (378)
 Receipts from disposal of investments                             -                    -                    1,544
 Purchases of property, plant and equipment                        (1,829)              (1,914)              (10,808)
 Purchase of intangibles                                           (30)                 (53)                 (205)
 Capitalised research and development costs                        (54)                 (627)                (1,708)
 Cash advances and loans made to other parties                     (415)                -                    -
 Proceeds from sale of fixed assets                                75                   -                    220
 Interest received                                                 160                  19                   119
 Net cash flows used in investing activities                       (2,156)              (2,575)              (11,216)
 Financing activities
 Proceeds of share issues                                          13,020               20,712               20,737
 Share-issue costs recognised through equity                       (1,386)              (607)                (562)
 Proceeds from bank or other borrowings                            -                    -                    67,939
 Repayment of bank or other borrowings                             (4,397)              (638)                (74,874)
 Interest and finance charges paid                                 (2,211)              (1,882)              (9,629)
 Capitalised borrowing costs                                       (600)                -                    -
 Repayments of lease liabilities                                   (2,200)              (2,730)              (10,533)
 Net cash inflow/(outflow) from financing activities               2,226                14,855               (6,922)
 Net increase/(decrease) in cash and cash equivalents              8,138                13,414               (7,328)
 Cash and cash equivalents at beginning of period                  36,399               39,460               39,460
 Effect of movements in exchange rate                              (1,755)              (169)                4,267
 Cash and cash equivalents at end of period                        42,782               52,705               36,399

 

The accompanying notes are an integral part of this consolidated financial
information.

 

 

Benchmark Holdings plc

Unaudited notes to the quarterly financial statements for the period ended 31
December 2022

 

 

1.     Basis of preparation

 

Benchmark Holdings plc (the 'Company') is a company incorporated and domiciled
in the United Kingdom. These consolidated quarterly financial statements as at
and for the three months ended 31 December 2022 comprises those of the Company
and its subsidiaries (together referred to as the 'Group').

 

These consolidated quarterly financial statements do not comprise statutory
accounts within the meaning of section 434 of the Companies Act 2006 and are
unaudited.  These financial statements do not include all the information
required for a complete set of IFRS financial statements.  However, selected
explanatory notes are included to explain events and transactions that are
significant to an understanding of the changes in the Group's financial
position and performance since the last annual financial statements.  The
Group's last annual statutory financial statements as at and for the year
ended 30 September 2022 were prepared in accordance with UK adopted
international accounting standards in conformity with the requirements of the
Companies Act 2006 as it applies to companies reporting under those standards
("Adopted IFRS") and are available from the Company's website at
www.benchmarkplc.com (http://www.benchmarkplc.com) .

 

The prior year comparatives are derived from audited financial information for
Benchmark Holdings PLC Group as set out in the Annual Report and Accounts for
the year ended 30 September 2022 and the unaudited financial information in
the Quarterly Financial Report for the three months ended 31 December 2021.
 The comparative figures for the financial year ended 30 September 2022 are
not the Company's statutory accounts for that financial year.  Those accounts
were approved by the Directors on 30 November 2022 and have been delivered to
the Registrar of Companies.  The audit report received on those accounts was
(i) unqualified and (ii) did not include a reference to any matters to which
the external auditor drew attention by way of emphasis without qualifying
their report, and (iii) did not contain a statement under section 498(2) or
(3) of the Companies Act 2006.

 

Statement of Compliance

 

These consolidated quarterly financial statements have been prepared in
accordance with UK and EU adopted IAS 34 'Interim Financial Reporting'. These
financial statements do not include all of the information required for the
full annual financial statements and should be read in conjunction with the
Group's last annual consolidated financial statements as at and for the year
ended 30 September 2022. These consolidated quarterly financial statements
were approved by the Board of Directors on 28 February 2022.

 

Going concern

 

The Group's business activities, together with the factors likely to affect
its future development, performance and position are set out in the Management
Report.

 

As at 31 December 2022 the Group had net assets of £315.9m (30 September
2022: £323.3m), including cash of £42.8m (30 September 2022: £36.4m) as
set out in the consolidated balance sheet. The Group made a loss for the
period of £0.7m (year ended 30 September 2022: loss £30.5m).

 

As noted in the Management Report, the business has continued to perform well
on the back of a good year in FY22.  All of the business areas have performed
in line with or ahead of management expectations.  The Directors have
reviewed forecasts and cash flow projections for a period of at least 12
months including downside sensitivity assumptions in relation to trading
performance across the Group to assess the impact on the Group's trading and
cash flow forecasts and on the forecast compliance with the covenants included
within the Group's financing arrangements.

 

In the downside analysis performed, the Directors considered severe but
plausible scenarios on the Group's trading and cash flow forecasts, firstly in
relation to continued roll out of the Ectosan®Vet and CleanTreat offering.
Sensitivities considered included modelling slower ramp up of the
commercialisation of Ectosan® Vet and CleanTreat® through delayed roll-out
of the revised operating model for the service, together with reductions in
expected biomass treated and reduced treatment prices. Key downside
sensitivities modelled in other areas included assumptions on slower
commercialisation of SPR shrimp, slower salmon egg sales growth both in Chile
and to land-based farms in Genetics, along with sensitivities on sales price
increases and potential supply constraints on CIS artemia in Advanced
Nutrition. Mitigating measures within the control of management have been
identified should they be required in response to these sensitivities,
including reductions in areas of discretionary spend, deferral of capital
projects and temporary hold on R&D for non-imminent products.

Following the refinancing of its NOK 850 million bond with the issue of a NOK
750 million unsecured green bond maturing in 2025 in FY22, which was due to
mature in June 2023, the USD15m RCF was refinanced in the quarter with a new
GBP20m RCF with a maturity of June 2025. Also in the quarter, our NOK 216m
loan facility (which had NOK 165.6m outstanding at the year end) which was set
to mature in October 2023, was combined with our NOK 17.5m overdraft facility
into a new loan facility of NOK 179.5m, with a new maturity date in a further
5 years no later than 15 January 2028. Following all of these refinancing
transactions, the Directors are satisfied there are sufficient facilities in
place during the assessment period.

 

The global economic environment is experiencing turbulence largely as a result
of the conflict in Eastern Europe with supply issues in a number of industries
impacted and inflation at high levels. Against this backdrop, the Group
continues to show resilience against these pressures, with financial
instruments in place to fix interest rates and with opportunities available to
mitigate globally high inflation rates, such that even under all of the above
sensitivity analysis, the Group has sufficient liquidity and resources
throughout the period under review whilst still maintaining adequate headroom
against the borrowing covenants.

 

The Directors therefore remain confident that the Group has adequate resources
to continue to meet its liabilities as and when they fall due within the
period of 12 months from the date of approval of these financial statements.
Based on their assessment, the Directors believe it remains appropriate to
prepare the financial statements on a going concern basis.

 

2.     Accounting policies

 

The accounting policies adopted are consistent with those used in preparing
the consolidated financial statements for the financial year ended 30
September 2022.

 

Taxes on income in the interim periods are accrued using the tax rate that
would be applicable to expected total earnings.

Alternative performance measures ('APMs')

The Directors measure the performance of the Group based on a range of
financial measures, including measures not recognised by EU-adopted IFRS.
These APMs may not be directly comparable with other companies' APMs, and the
Directors do not intend these as a substitute for, or superior to, IFRS
measures.

Directors have presented the performance measures Adjusted EBITDA, Adjusted
Operating Profit, Adjusted Profit Before Tax and Adjusted EBITDA excluding
fair value movement on biological assets because they monitor performance at a
consolidated level using these and believe that these measures are relevant to
an understanding of the Group's financial performance (see note 10).
Furthermore, the Directors also refer to current period results using constant
currency, which are derived by retranslating current period results using the
prior year's foreign exchange rates.

Use of estimates and judgements

The preparation of quarterly financial information requires management to make
certain judgements, estimates and assumptions that affect the application of
accounting policies and the reported amounts of assets and liabilities, income
and expense. Actual amounts may differ from these estimates.

 

In preparing these quarterly financial statements the critical judgements made
by management in applying the Group's accounting policies and the key sources
of estimation uncertainty were the same as those applied to the consolidated
financial statements for the year ended 30 September 2022.

 

3.     Segment information

 

Operating segments are reported in a manner consistent with the reports made
to the chief operating decision maker. It is considered that the role of chief
operating decision maker is performed by the Board of Directors.

 

The Group operates globally and for management purposes is organised into
reportable segments based on the following business areas:

 

·      Genetics - harnesses industry leading salmon breeding
technologies combined with state-of-the-art production facilities to provide a
range of year-round high genetic merit ova and technical services.

·      Advanced Nutrition - manufactures and provides technically
advanced nutrition and health products to the global aquaculture industry.

·      Health -provides health products and services to the global
aquaculture market.

In order to reconcile the segmental analysis to the consolidated income
statement, corporate and inter-segment sales are also shown. Corporate sales
represent revenues earned from recharging certain central costs to the
operating business areas, together with unallocated central costs.

Measurement of operating segment profit or loss

Inter-segment sales are priced along the same lines as sales to external
customers, with an appropriate discount being applied to encourage use of
Group resources at a rate acceptable to local tax authorities.  This policy
was applied consistently throughout the current and prior period.

 

 

Reconciliations of segmental information to IFRS measures

 

  Segmental Revenue
  All figures in £000's        Q1 2023       Q1 2022       FY 2022

(unaudited)
(unaudited)
(audited)
   Genetics                   21,439        15,195        58,008
   Advanced Nutrition         22,680        19,059        80,286
   Health                     10,385        5,777         20,135
   Corporate                  1,437         1,406         5,120
   Inter-segment sales        (1,446)       (1,423)       (5,272)
   Total                      54,495        40,014        158,277

  Segmental Adjusted EBITDA
  All figures in £000's        Q1 2023       Q1 2022       FY 2022

(unaudited)
(unaudited)
(audited)
   Genetics                   2,563         3,263         15,980
   Advanced Nutrition         5,297         4,320         19,017
   Health                     4,067         547           108
   Corporate                  (960)         (705)         (3,924)
   Total                      10,967        7,425         31,181

 

 

  Reconciliation of Reportable Segments Adjusted EBITDA to Loss before
 taxation
  All figures in £000's                                                   Q1 2023       Q1 2022       FY 2022

(unaudited)
(unaudited)
(audited)
  Total reportable segment Adjusted EBITDA                               11,927        8,130         35,105
  Corporate Adjusted EBITDA                                              (960)         (705)         (3,924)
  Adjusted EBITDA                                                        10,967        7,425         31,181
  Exceptional items                                                      (972)         -             16
  Depreciation and impairment                                            (4,615)       (4,495)       (19,897)
  Amortisation and impairment                                            (5,502)       (4,388)       (19,161)
  Net finance income/(costs)                                             222           (2,224)       (15,316)
  Profit/(loss) before taxation                                          100           (3,682)       (23,177)

 

4.     Revenue

 

The Group's operations and main revenue streams are those described in its
financial statements to 30 September 2022. The Group's revenue is derived from
contracts with customers.

Disaggregation of revenue

In the following tables, revenue is disaggregated by primary geographical
market and by sales of goods and services. The table includes a reconciliation
of the disaggregated revenue with the Group's reportable segments (see note
3).

Sale of goods and provision of services

                          3 months ended 31 December 2022 (unaudited)
 All figures in £000's     Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total
  Sale of goods           21,121      22,672                7,449      -            -                      51,242
  Provision of services   317         -                     2,936      -            -                      3,253
  Inter-segment sales     1           8                     -          1,437        (1,446)                -
                          21,439      22,680                10,385     1,437        (1,446)                54,495

                          3 months ended 31 December 2021 (unaudited)
 All figures in £000's     Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total
  Sale of goods           14,509      19,048                3,251      -            -                      36,808
  Provision of services   680         -                     2,526      -            -                      3,206
  Inter-segment sales     6           11                    -          1,406        (1,423)                -
                          15,195      19,059                5,777      1,406        (1,423)                40,014

                          12 months ended 30 September 2022 (audited)
 All figures in £000's     Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total
  Sale of goods           53,978      80,191                13,528     -            -                      147,697
  Provision of services   3,973       -                     6,607      -            -                      10,580
  Inter-segment sales     57          95                    -          5,120        (5,272)                -
                          58,008      80,286                20,135     5,120        (5,272)                158,277

Sale of goods and provision of services (continued)

Primary geographical markets

 

                         3 months ended 31 December 2022 (unaudited)
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total
  Norway                 16,884      90                    8,295      -            -                      25,269
  India                  -           4,203                 -          -            -                      4,203
  Singapore              -           39                    -          -            -                      39
  Turkey                 6           2,204                 -          -            -                      2,210
  Ecuador                20          1,740                 -          -            -                      1,760
  Greece                 -           2,269                 -          -            -                      2,269
  Faroe Islands          1,095       -                     229        -            -                      1,324
  UK                     737         19                    42         -            -                      798
  Chile                  12          2                     254        -            -                      268
  Rest of Europe         2,062       1,622                 -          -            -                      3,684
  Rest of World          622         10,484                1,565      -            -                      12,671
  Inter-segment sales    1           8                     -          1,437        (1,446)                -
                         21,439      22,680                10,385     1,437        (1,446)                54,495

                         3 months ended 31 December 2021 (unaudited)
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total
  Norway                 9,679       112                   4,668      -            -                      14,459
  India                  140         4,008                 -          -            -                      4,148
  Singapore              -           1,138                 -          -            -                      1,138
  Turkey                 -           1,694                 -          -            -                      1,694
  Ecuador                -           1,064                 -          -            -                      1,064
  Greece                 -           1,639                 -          -            -                      1,639
  Faroe Islands          892         1                     130        -            -                      1,023
  UK                     1,957       14                    88         -            -                      2,059
  Chile                  116         -                     403        -            -                      519
  Rest of Europe         1,771       1,303                 -          -            -                      3,074
  Rest of World          634         8,075                 488        -            -                      9,197
  Inter-segment sales    6           11                    -          1,406        (1,423)                -
                         15,195      19,059                5,777      1,406        (1,423)                40,014

 

Primary geographical markets (continued)

 

                         12 months ended 30 September 2022 (audited)
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total
  Norway                 34,666      965                   15,571     -            -                      51,202
  India                  619         12,001                -          -            -                      12,620
  Singapore              -           7,044                 -          -            -                      7,044
  Turkey                 -           6,419                 -          -            -                      6,419
  Ecuador                18          6,472                 -          -            -                      6,490
  Greece                 2           6,197                 -          -            -                      6,199
  Faroe Islands          5,465       9                     587        -            -                      6,061
  UK                     4,318       93                    199        -            -                      4,610
  Chile                  1,006       15                    871        -            -                      1,892
  Rest of Europe         7,110       4,056                 -          -            -                      11,166
  Rest of World          4,747       36,920                2,907      -            -                      44,574
  Inter-segment sales    57          95                    -          5,120        (5,272)                -
                         58,008      80,286                20,135     5,120        (5,272)                158,277

 

5.     Exceptional items

 

Items that are material because of their size or nature, non-recurring and
whose significance is sufficient to warrant separate disclosure and
identification within the consolidated financial statements are referred to as
exceptional items. The separate reporting of exceptional items helps to
provide an understanding of the Group's underlying performance.

 

 All figures in £000's                        Q1 2023       Q1 2022       FY 2022

(unaudited)
(unaudited)
(audited)
  Exceptional restructuring costs             948            -            1,229
  Costs/(credit) in relation to disposals     24             -            (1,245)
 Total exceptional items                      972           -             (16)

 

Exceptional restructuring costs include £863,000 of legal and professional
costs in relation to preparing for listing the Group on the Oslo stock
exchange, and £85,000 relating to other restructuring costs. The comparative
figure for FY 2022 figure includes £843,000 of legal and professional costs
in relation to preparing for listing the Group on the Oslo stock exchange, and
£276,000 relating to other restructuring costs.

 

Costs in relation to disposals totaling £24,000 are additional costs relating
to disposals that occurred in 2020. The comparative figure for FY 2022 figure
includes a credit of £1,203,000 in relation to additional contingent
consideration received and receivable from disposals in previous years
(£294,000 relating to the disposal of Aquaculture UK on 7 February 2020, and
£909,000 relating to the disposal of Improve International Limited and its
subsidiaries on 23 June 2020) together with legal fees, lease costs and
disposal items (net of proceeds received) totalling £42,000 relating to
additional costs and disposals proceeds relating to disposals that occurred in
2020.

 

6.     Taxation

 

 All figures in £000's                                     Q1 2023       Q1 2022       FY 2022

(unaudited)
(unaudited)
(audited)

 Analysis of charge in period
 Current tax:
 Current income tax expense on profits for the period      1,838         2,359         11,727
 Adjustment in respect of prior periods                    -             5             (39)
 Total current tax charge                                  1,838         2,364         11,688

 Deferred tax:
 Origination and reversal of temporary differences         (1,059)       (937)         (4,414)
 Deferred tax movements in respect of prior periods        -             -             -
 Total deferred tax credit                                 (1,059)       (937)         (4,414)
                                                                                       -
 Total tax charge                                          779           1,427         7,274

 

7.     Loss per share

 

Basic loss per share is calculated by dividing the loss attributable to
ordinary equity holders of the Company by the weighted average number of
ordinary shares in issue during the period.

                                                            Q1 2023       Q1 2022       FY 2022

(unaudited)
(unaudited)
(audited)
 Loss attributable to equity holders of the parent (£000)   (1,283)       (5,357)       (32,087)
 Weighted average number of shares in issue (thousands)     710,087       681,271       698,233
 Basic loss per share (pence)                               (0.18)        (0.79)        (4.60)

 

Diluted loss per share is calculated by adjusting the weighted average number
of ordinary shares outstanding to assume conversion of all dilutive potential
ordinary shares. This is done by calculating the number of shares that could
have been acquired at fair value (determined as the average market price of
the Company's shares for the period) based on the monetary value of the
subscription rights attached to outstanding share options and warrants. The
number of shares calculated above is compared with the number of shares that
would have been issued assuming the exercise of the share options and
warrants.

 

Therefore, the Company is required to adjust the earnings per share
calculation in relation to the share options that are in issue under the
Company's share-based incentive schemes, and outstanding warrants. However, as
any potential ordinary shares would be anti-dilutive due to losses being made
there is no difference between Basic loss per share and Diluted loss per share
for any of the periods being reported.

 

A total of 4,053,469 potential ordinary shares have not been included within
the calculation of statutory diluted loss per share for the year (30 September
2022: 6,240,304 and 31 December 2021: 5,782,581). These potential ordinary
shares could dilute earnings/loss per share in the future.

 

8.     Loans and borrowings

 

 

 All figures in £000's       Q1 2023       Q1 2022       FY 2022

(unaudited)
(unaudited)
(audited)
 Non-Current
 2025 750m NOK Loan notes    61,866        -             61,054
 2023 850m NOK Loan notes    -             75,592        -
 Bank borrowings             17,201        18,578        17,226
 Lease liabilities           8,891         15,949        14,765
                             87,958        110,119       93,045
 Current
 Bank borrowings             1,603         1,592         5,569
 Lease liabilities           14,624        5,280         11,522
                             16,227        6,872         17,091
 Total loans and borrowings  104,185       116,991       110,136

 

On 27 September 2022, the Group successfully issued a new unsecured floating
rate listed green bond of NOK 750m. The bond which matures in September 2025,
has a coupon of three-month NIBOR + 6.50% p.a. with quarterly interest
payments, and is to be listed on the Oslo Stock Exchange. The proceeds were
used to repay its existing NOK 850m floating rate listed bond, originally
raised in June 2019.

 

On 21 November 2022, the Group refinanced its USD15m RCF, which was provided
by DNB Bank ASA (50%) and HSBC UK Bank PLC (50%), with a secured GBP20m RCF
provided by DNB Bank ASA, maturing on 27 June 2025. The margin on this
facility is a minimum of 2.75% and a maximum of 3.25%, dependent upon the
leverage of the Group above the relevant risk free reference or IBOR rates
depending on which currency is drawn.  The facility was undrawn at 31
December 2022.

 

Additionally, during the period, on 1 November 2022, the Group's Nordea Bank
term loan of NOK 165.6m, which had a term loan of five years ending in
November 2023 and interest rate of 2.5% above three month NIBOR, was
refinanced together with an existing undrawn overdraft facility into a new
loan facility of NOK 179.5m with a new maturity date in a further five years
no later than 15 January 2028. Other terms of this facility remain the same.

 

 

9.     Share capital and additional paid-in share capital

 

                                               Number       Share Capital  Additional paid-in

share capital
 Allotted, called up and fully paid                         £000           £000
 Ordinary shares of 0.1 pence each
 Balance at 30 September 2022                  703,960,798  704            420,824
 Shares issued through placing and open offer  35,189,350   35             11,599
 Exercise of share options                     45,000       -              -
 Balance at 31 December 2022                   739,195,148  739            432,423

 

On 15 December 2022, the Company issued 35,189,350 new ordinary shares of 0.1
pence each by way of a placing and subscriptions at an issue price of 37.0
pence per share. Gross proceeds of £13.0m were received for the placing and
subscription shares. Non-recurring costs of £1.4m were in relation to the
share issues and this has been charged to the share premium account (presented
within additional paid-in share capital).

 

 

10.   Alternative performance measures and other metrics

 

Management has presented the performance measures EBITDA, Adjusted EBITDA,
Adjusted EBITDA before fair value movement in biological assets, Adjusted
Operating Profit and Adjusted Profit Before Tax because it monitors
performance at a consolidated level using these and believes that these
measures are relevant to an understanding of the Group's financial
performance.

Adjusted EBITDA which reflects underlying profitability, is earnings before
interest, tax, depreciation, amortisation, impairment, and exceptional items
and is shown on the Income Statement.

Adjusted EBITDA before fair value movements in biological assets, which is
Adjusted EBITDA before the non-cash fair value movements in biological assets
arising from their revaluation in line with International Accounting
Standards.

Adjusted Operating Profit is operating loss before exceptional items and
amortisation and impairment of intangible assets excluding development costs
as reconciled below.

Adjusted Profit Before Tax is earnings before tax, amortisation and impairment
of intangibles assets excluding development costs, and exceptional items as
reconciled below. These measures are not defined performance measures in IFRS.
The Group's definition of these measures may not be comparable with similarly
titled performance measures and disclosures by other entities.

 

Reconciliation of Adjusted Operating Profit to Operating Loss

 

 All figures in £000's                                                             Q1 2023       Q1 2022       FY 2022

(unaudited)
(unaudited)
(audited)
 Revenue                                                                           54,495        40,014        158,277
 Cost of sales                                                                     (30,268)      (20,515)      (75,149)
 Gross profit                                                                      24,227        19,499        83,128
 Research and development costs                                                    (1,563)       (1,647)       (6,691)
 Other operating costs                                                             (11,753)      (9,923)       (44,661)
 Depreciation and impairment                                                       (4,615)       (4,495)       (19,897)
 Amortisation of capitalised development costs                                     (617)         (448)         (2,165)
 Share of loss of equity accounted investees net of tax                            56            (504)         (595)
 Adjusted operating profit                                                         5,735         2,482         9,119
 Exceptional items                                                                 (972)         -             16
 Amortisation and impairment of intangible assets excluding development costs      (4,885)       (3,940)       (16,996)
 Operating loss                                                                    (122)         (1,458)       (7,861)

 

 

Reconciliation of Loss Before Taxation to Adjusted Profit Before Tax

 All figures in £000's                                                             Q1 2023       Q1 2022       FY 2022

(unaudited)
(unaudited)
(audited)

 Profit/(loss) before taxation                                                     100           (3,682)       (23,177)
 Exceptional items                                                                 972           -             (16)
 Amortisation and impairment of intangible assets excluding development costs      4,885         3,940         16,996
 Adjusted profit before tax                                                        5,957         258           (6,197)

 

 

Other Metrics

 All figures in £000's                       Q1 2023       Q1 2022       FY 2022

(unaudited)
(unaudited)
(audited)
 Total R&D Investment
 Research and development costs              1,563         1,647         6,691
 Internal capitalised development costs      54            627           1,708
 Total R&D investment                        1,617         2,274         8,399

 

 

 All figures in £000's                                                    Q1 2023       Q1 2022       FY 2022

(unaudited)
(unaudited)
(audited)
 Adjusted EBITDA excluding fair value movement in biological assets
 Adjusted EBITDA                                                         10,967        7,425         31,181
 Exclude fair value movement                                             1,154         96            (1,595)
 Adjusted EBITDA excluding fair value movement in biological assets      12,121        7,521         29,586

 

Liquidity

 

A key financial covenant is a minimum liquidity of £10m, defined as cash plus
undrawn facilities.

 

                              31 December 2022
 All figures in £000's        (unaudited)
 Cash and cash equivalents    42,782
 Undrawn bank facility        20,000
                              62,782

 

The undrawn bank facility relates to the RCF facility.  At 31 December 2022,
£nil of the RCF was drawn (30 September 2022: £4m and 31 December 2021:
£nil), leaving £20m undrawn (30 September 2022: £9.4m and 31 December 2021:
£11.1m).

 

 

11.   Net debt

Net debt is cash and cash equivalents less loans and borrowings.

 

                                                                     31 December 2022  31 December 2021  30 September 2022
 All figures in £000's                                               (unaudited)       (unaudited)       (audited)
 Cash and cash equivalents                                           42,782            52,705            36,399
 Loans and borrowings (excluding lease liabilities) - current        (1,603)           (1,592)           (5,569)
 Loans and borrowings (excluding lease liabilities) - non-current    (79,067)          (94,170)          (78,280)
 Net debt excluding lease liabilities                                (37,888)          (43,057)          (47,450)
 Lease liabilities - current                                         (14,624)          (5,280)           (11,522)
 Lease liabilities - non-current                                     (8,891)           (15,949)          (14,765)
 Net debt                                                            (61,403)          (64,286)          (73,737)

 

12.   Post balance sheet events

 

On 15 February 2023, the Group purchased the minority interest's shareholding
of 14,981,272 shares in Benchmark Genetics Iceland HF for €9,000,000.
Following this acquisition, Benchmark Genetics Limited, a subsidiary of
Benchmark Holdings PLC, now owns 100% of the share capital of Benchmark
Genetics Iceland HF.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  QRFPPUQGPUPWUUR

Recent news on Benchmark Holdings

See all news